US 12,403,158 B1
Phytochemical/ nutraceutical composition for multimodal prophylaxis against and treatment of viral and bacterial infection and inflammation
David A. Cuddeback, Kirkwood, NY (US); and Thomas J. Lynch, Elverson, PA (US)
Filed by David A Cuddeback, Kirkwood, NY (US)
Filed on Jan. 11, 2024, as Appl. No. 18/410,512.
Application 18/410,512 is a division of application No. 18/094,541, filed on Jan. 9, 2023, granted, now 11,896,611.
Application 18/094,541 is a division of application No. 17/682,300, filed on Feb. 28, 2022, granted, now 12,186,341.
Application 17/682,300 is a continuation in part of application No. 16/848,393, filed on Apr. 14, 2020, abandoned.
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 36/00 (2006.01); A61K 9/00 (2006.01); A61K 9/48 (2006.01); A61K 31/05 (2006.01); A61K 31/12 (2006.01); A61K 31/198 (2006.01); A61K 31/202 (2006.01); A61K 31/352 (2006.01); A61K 31/355 (2006.01); A61K 31/375 (2006.01); A61K 31/4525 (2006.01); A61K 33/30 (2006.01); A61K 36/15 (2006.01); A61K 36/185 (2006.01); A61K 36/233 (2006.01); A61K 36/28 (2006.01); A61K 36/324 (2006.01); A61K 36/328 (2006.01); A61K 36/537 (2006.01); A61K 36/74 (2006.01); A61K 36/82 (2006.01)
CPC A61K 33/30 (2013.01) [A61K 9/0053 (2013.01); A61K 9/48 (2013.01); A61K 31/05 (2013.01); A61K 31/12 (2013.01); A61K 31/198 (2013.01); A61K 31/202 (2013.01); A61K 31/352 (2013.01); A61K 31/355 (2013.01); A61K 31/375 (2013.01); A61K 31/4525 (2013.01); A61K 36/15 (2013.01); A61K 36/185 (2013.01); A61K 36/233 (2013.01); A61K 36/28 (2013.01); A61K 36/324 (2013.01); A61K 36/328 (2013.01); A61K 36/537 (2013.01); A61K 36/74 (2013.01); A61K 36/82 (2013.01)] 11 Claims
 
1. A nutraceutical composition in capsule form for preventing or mollifying viral or bacterial infection, and also for preventing or mollifying viral or bacterial tissue inflammation, the composition comprising:
an effective amount of vitamin C;
an effective amount of vitamin E;
an effective amount of zinc;
effective amounts of wide-spectrum anti-infectious phytochemicals comprising extracted fulvic acid and at least one other anti-infectious phytochemical;
effective amounts of an anti-inflammatory nutraceutical comprising an omega-3 fatty acid, wherein the omega-3 fatty acid comprises eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or both; and
effective amounts of anti-inflammatory phytochemicals comprising Boswellia serrata extract and at least one additional anti-inflammatory phytochemical.